US/UK/Canada

Share

Pick a time period -
Tags ( Active)

STRONGBRIDGE BIOPHARMA PLC ANNOUNCES LAUNCH OF ITS PROPOSED INITIAL U.S. PUBLIC OFFERING

September 21, 2015 - Dublin, Ireland and Trevose, Pa., USA – Strongbridge Biopharma plc announced today that it has commenced its initial U.S. public offering of 4,250,000 ordinary shares. In connection with this offering, Strongbridge Biopharma expects to grant to the underwriters a 30-day option to purchase up to an additional 637,500 ordinary shares. The ordinary shares are currently quoted on the NOTC, A-list in Norway under the symbol “SBBP,” and Strongbridge Biopharma has applied to list its ordinary shares on The NASDAQ Global Market under the same symbol. BofA Merrill Lynch and

Strongbridge Biopharma plc Announces Appointment of Garheng Kong, M.D., Ph.D., MBA, to its Board of Directors

September 15, 2015 – Dublin, Ireland and Trevose, Pa., USA – Strongbridge Biopharma plc announced today that Garheng Kong, M.D., Ph.D., MBA, founder and managing partner of HealthQuest Capital, has been appointed to the Company’s Board of Directors, effective immediately. The Company also announced today that Joseph M. Mahady, who has served as a director, has elected to step down from the Strongbridge Biopharma Board of Directors. “We are pleased to welcome Garheng to our Board of Directors during this important period of growth and evolution for Strongbridge Biopharma,” said Matthew

Strongbridge Biopharma plc Announces Appointment of Matthew Pauls to its Board of Directors

September 4, 2015 – Dublin, Ireland and Trevose, Pa., USA – Strongbridge Biopharma plc, formerly known as Cortendo plc, (the “Company”), announced today that Matthew Pauls, president and chief executive officer of Strongbridge Biopharma plc, has been appointed to the Company’s Board of Directors. Mr. Pauls’s appointment as a director is effective immediately. The Company also announced that Eigil Stray Spetalen, who has served as a director and previously as chairman of Cortendo AB, has elected to step down from the Cortendo AB Board of Directors. “We are pleased to welcome Matt to

Cortendo plc Changes Name to Strongbridge Biopharma plc

Dublin, Ireland and Trevose, Pa., USA – September 4, 2015 – Cortendo plc announced today that the Company has changed its name to Strongbridge Biopharma plc. Strongbridge Biopharma will become effective immediately and the new logo and corporate branding elements will be rolled out in the near future. Under the new corporate name, Strongbridge Biopharma will remain committed to building a biopharmaceutical company focused on the development, in-licensing, acquisition and eventual commercialization of complementary product candidates across multiple franchises that target rare diseases.

Cortendo plc Announces Reverse Share Split

September 4, 2015 – Dublin, Ireland and Trevose, Pa., USA – Cortendo plc today announced that immediately following the settlement of its exchange offer to acquire any and all issued ordinary shares of Cortendo AB (publ), it will effect a 1-for-11 reverse share split of its ordinary shares. On or about September 8, 2015, each 11 shares of the Company’s issued and outstanding ordinary shares will be converted into 1 ordinary share. Beneficial interests in the shares (in the form of depositary receipts) will begin trading on the NOTC on a split-adjusted basis on or about September 9, 2015.

Cortendo Announces Filing of Registration Statement for Proposed Initial Public Offering

August 31, 2015 – Göteborg, Sweden and Trevose, Pa., USA – Cortendo AB (publ) [ticker: CORT on NOTC-A], today announced it has filed a registration statement on Form F-1 with the Securities and Exchange Commission relating to the proposed initial public offering of its ordinary shares. The number of shares to be offered and the price range for the proposed offering have not yet been determined. Cortendo AB has applied to list its ordinary shares on The NASDAQ Global Market under the ticker symbol “SBBP.” BofA Merrill Lynch and Stifel are acting as joint book-running managers of the

Cortendo Announces Plans to Redomicile the Cortendo Group’s Parent Company from Sweden to Ireland By Means of an Exchange Offer

August 3, 2015 – Göteborg, Sweden and Trevose, Pa., USA – Cortendo AB (publ) [ticker: CORT on NOTC-A] (the “Company”) today announced its intention to relocate the parent company of the Cortendo group from Sweden to Ireland.  The Company is contemplating effecting such redomiciliation through an exchange offer in which Cortendo plc, a newly incorporated Irish public limited company incorporated on behalf of the Company, would offer to acquire any and all issued ordinary shares of the Company in exchange for beneficial interests in ordinary shares of Cortendo plc in the form of depositary

Cortendo Announces Plans to Conduct Registered Initial Public Offering of Its Common Shares

July 20, 2015 – Göteborg, Sweden and Trevose, Pa., USA – Cortendo AB (publ) [ticker: CORT on NOTC-A] today announced that the Company plans to conduct a registered initial public offering of common shares in the United States. This announcement is being made pursuant to and in accordance with Rule 135 under the Securities Act of 1933. As required by Rule 135, this press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would

Cortendo Provides 2015 Half-Year Update on Corporate Progress

Cortendo Expands Board of Directors and Management TeamCortendo Provides Update on COR-003 Phase 3 Clinical Development ProgramCortendo Builds Rare Endocrine Disease Franchise with Completion of Transactions for Two-Late Stage AssetsCortendo Closes Aggregate $59.6 Million in Two Private Placement Financings and Provides Update on Cash Position July 2, 2015 – Göteborg, Sweden and Trevose, Pa., USA – Cortendo AB (publ) [ticker: CORT on NOTC-A], a biopharmaceutical company focused on rare endocrine disorders and other rare diseases, today announced an update on 2015 half-year

Cortendo Adds Two Late-Stage Assets to Its Rare Endocrine Disease Franchise and Announces Related $33.2 Million Financing

Cortendo Enters Into Agreements to Acquire Aspireo Pharmaceuticals' Somatoprim (DG3173) and In-License Antisense Therapeutics' ATL1103Cortendo Expands Investor Base Through New Private Placement May 15, 2015 – Göteborg, Sweden and Trevose, Pa., USA – Cortendo AB (publ) [ticker: CORT on NOTC-A], a biopharmaceutical company focused on rare endocrine disorders and other rare diseases, today announced that it has entered into an agreement to acquire Aspireo Pharmaceuticals’ Somatoprim (DG3173), an investigational compound being studied for the treatment of acromegaly. Cortendo also

Cortendo and Antisense Therapeutics Announce Licensing Agreement for ATL1103 for Acromegaly

May 14, 2015 – Goteborg, Sweden and Trevose, Pa., USA and Victoria, Australia – Cortendo AB (publ) [ticker: CORT on NOTC-A], a biopharmaceutical company focused on rare endocrine disorders and other rare diseases, and Antisense Therapeutics Limited [ticker: ANP on ASX] today announced that the companies have entered into an exclusive license agreement that provides Cortendo with development and commercialization rights to Antisense Therapeutics’ ATL1103 for endocrinology applications. Under the terms of the agreement, Cortendo will provide Antisense Therapeutics with an initial upfront

Cortendo AB Joins National Organization for Rare Disorders (NORD)® Corporate Council

Leaders in Rare Disease Community Unite for National Cushing’s Syndrome Awareness Day on April 8 RADNOR, Pa. and DANBURY, Conn., April 8, 2015 – Cortendo AB (publ) [ticker: CORT on NOTC-A], a global biopharmaceutical company focused on rare endocrine disorders and other rare diseases, and the National Organization for Rare Disorders (NORD)®, a leading, independent nonprofit organization committed to the identification, treatment and cure of rare diseases, today announced that Cortendo has joined NORD’s Corporate Council. The NORD Corporate Council is composed of a select group of

Cortendo AB Announces Appointments of A. Brian Davis as Chief Financial Officer and Stephen Long as Chief Legal Officer

March 23, 2015 – Göteborg, Sweden and Radnor, Pa., USA -- Cortendo AB (publ) [ticker: CORT on NOTC-A], a global biopharmaceutical company focused on orphan endocrine disorders and other rare diseases, today announced the appointments of A. Brian Davis to the position of chief financial officer (CFO) and Stephen Long to the position of chief legal officer. Mr. Davis and Mr. Long will report to Matthew Pauls, president and chief executive officer, and will join the Company’s management team, effective immediately. “We are pleased to welcome Brian and Stephen to Cortendo’s management team,”

Cortendo AB Names John H. Johnson as Chairman and Appoints Richard Kollender as Director

March 18, 2015 – Göteborg, Sweden and Radnor, Pa., USA -- Cortendo AB (publ) [ticker: CORT on NOTC-A], a global biopharmaceutical company focused on orphan endocrine disorders, today announced the appointments of John H. Johnson as chairman of the board of directors and Richard Kollender as a director. These appointments, proposed by the nomination committee, were approved by shareholders during the Extraordinary General Meeting on March 17. “We welcome the additions of John and Rich to Cortendo’s board of directors,” said Matthew Pauls, president and chief executive officer of Cortendo.

Election of new board members by Extraordinary General Meeting of Cortendo AB

March 17, 2015 -- Radnor, Penn., U.S. and Göteborg, Sweden -- Cortendo AB (publ) [ticker: CORT on NOTC-A], a global biopharmaceutical company focused on orphan endocrine disorders, today held an Extraordinary General Meeting in Göteborg. Approximately 57% of the 159,080,722 million outstanding shares were represented at the Extraordinary General Meeting. In accordance with the Nomination Committee’s proposal, the Extraordinary General Meeting elected, for the period until the end of the next annual general meeting, John H. Johnson as new chairman of the board of directors and Richard

Interim report for the fourth quarter and full year 2014

CORTENDO REPORTS RESULTS AND ACTIVITIES FOR THE FOURTH QUARTER AND FULL YEAR 2014HIGHLIGHTS - Q4 2014 AND POST PERIOD · Cortendo closed two private placement financings totaling approximately SEK 302 million ($37 million) during Q4 2014 and Q1 2015 with several well-known institutional specialist healthcare investors. Cortendo is pursuing a U.S. financing and listing strategy. · COR-003 (levoketoconazole) Phase 3 SONICS trial - continued progress on trial implementation and recruitment. Twenty-seven trial sites have now been activated, and ten patients have been dosed with COR-

Cortendo Announces Proposed Changes to Board of Directors

February 27, 2015 -- Göteborg, Sweden and Radnor, Penn., USA -- Cortendo AB  (publ) [ticker: CORT on NOTC-A], a global biopharmaceutical company focused on orphan endocrine disorders, today announced changes to the Company’s board of directors proposed by the company’s nomination committee. John H. Johnson has been nominated to serve as chairman and Richard Kollender to serve as a director. Both nominations are subject to approval by the Extraordinary General Meeting of Shareholders in Cortendo, scheduled to be held on March 17, 2015. John H. Johnson has more

Cortendo to Present at Upcoming Investor Conferences

February 26, 2015 – Göteborg, Sweden and Radnor, Penn., USA – Cortendo AB  [ticker: CORT on NOTC-A], a global biopharmaceutical company focused on orphan endocrine disorders, today announced President and CEO Matthew Pauls will present corporate updates at three investor conferences in March:  Cowen and Company 35th Annual Health Care Conference Presentation: March 2, 2015 at 3:30 p.m. EST in the St. Botolph roomLocation: The Boston Marriott Copley Place, Boston, Mass. 27th Annual ROTH Conference (

Cortendo to Join Patients, Families and Pennsylvania Legislators to Raise Awareness for Rare Diseases

February 23, 2015 -- Harrisburg, PA, USA – Cortendo AB  [ticker: CORT on NOTC-A], a global biopharmaceutical company focused on developing new solutions for rare diseases that is based in Radnor, Penn., is pleased to participate in the Rare Disease Day® event at the Pennsylvania State Capitol Building on Tuesday, February 24. Matthew Pauls, President and CEO of Cortendo, joins patients and their families, physicians and legislators to help raise awareness for the 30 million Americans currently living with a rare disease. The event is Tuesday, February 24, 11:30 a.

Cortendo Completes $26.4M in Private Placement from Leading U.S. and EU Investors

February 11, 2015 -- Göteborg, Sweden and Radnor, Penn., USA -- Cortendo AB  [ticker: CORT on NOTC-A], a global biopharmaceutical company focused on orphan endocrine disorders, today announced that it closed a previously announced private placement totaling approximately $26.4 million. Including the $11 million private placement announced in October, the company has raised a total of approximately $37 million in the last five months. The Company has closed on transactions with leading U.S. institutional specialist healthcare investors RA Capital Management, New

Cortendo to Present at the 17th Annual BIO CEO & Investor Conference

February 2, 2015 -- Göteborg, Sweden and Radnor, Penn., USA -- Cortendo AB  [ticker: CORT on NOTC-A], a global biopharmaceutical company initially focused on orphan endocrine disorders, today announced that Matthew Pauls, President and CEO, will provide a company update at the 17th Annual BIO CEO & Investor Conference in New York City. The presentation is on Feb. 9, 2015, at 1:30 p.m. in the Park South room at the Waldorf Astoria hotel. This presentation will be webcast and available on the “Presentations” page in the Investor section of the company’s website at

COR-003 Phase 3 Study Protocol to be Presented at ENDO 2015: The Endocrine Society’s 97th Annual Meeting & Expo

January 29, 2015 -- Radnor, Penn., U.S. and Göteborg, Sweden -- Cortendo AB [ticker: CORT on NOTC-A], a global biopharmaceutical company initially focused on orphan endocrine disorders, today announced that it will present the study protocol of its global Phase 3 study of COR-003 in patients with endogenous Cushing’s syndrome at ENDO 2015: The Endocrine Society’s 97th Annual Meeting & Expo March 5-8 in San Diego, CA. This abstract will also be published in the April issue of Endocrine Reviews. Additional information on the Cortendo presentation: Title: An Open-label Study to Assess

The Journal Diabetes Publishes Pre-clinical Data on Cortendo’s Novel Diabetes Treatment, BP-2001

January 28, 2015 -- Göteborg, Sweden and Radnor, Penn., USA – Cortendo AB [ticker: CORT on NOTC-A], a global biopharmaceutical company focused on orphan endocrine disorders, is pleased to announce that the journal Diabetes published a scientific paper reporting on a pre-clinical study that details the glucose-lowering effect of BP-2001, an orally administered genetically modified probiotic being studied for the treatment of type 1 and type 2 diabetes. “The pre-clinical data show that BP-2001 demonstrated the ability to reprogram intestinal endocrine cells into glucose-responsive insulin-

There are no items matching the current filter
There are no more items matching the current filter
Back to top